Allergo Journal

, Volume 27, Issue 6, pp 22–30 | Cite as

Comparison of sublingual immunotherapy and oral immunotherapy in peanut allergy

  • Wenming Zhang
  • Sayantani B. Sindher
  • Vanitha Sampath
  • Kari NadeauEmail author
Mini-Review Sublingual and oral immunotherapy in peanut allergy


The prevalence of food allergy has been increasing over the past few decades at an alarming rate with peanut allergy affecting about 2 % of children. Both oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) have shown promise as a treatment option for peanut allergy. Immunotherapy induces desensitization and reduces the risk of reaction during accidental ingestion and may also enable those who are successfully desensitized to include the food allergen in their diet. OIT has been very well studied and has been found to be more efficacious than SLIT with an acceptable safety profile. However, SLIT is associated with fewer side effects. Studies indicate that a combination of SLIT and OIT may together induce a significant increase in challenge thresholds with fewer adverse events. More head-to-head clinical trials that directly compare OIT and SLIT as well as SLIT and OIT combination studies are warranted.



Allergen-specific immunotherapy


Bronchial hyper-responsiveness


B regulatory cells


Double-blind placebo-controlled food challenge


Food allergy


Oral immunotherapy


Probiotic with peanut OIT


Sublingual immunotherapy


Sustained unresponsiveness




Regulatory T cells


oral immunotherapy sublingual immunotherapy peanut allergy food allergy 


  1. 1.
    Savage J, Johns CB. Food allergy: epidemiology and natural history. Immunol Allergy Clin North Am 2015;35:45–59CrossRefGoogle Scholar
  2. 2.
    Warren CM, Otto AK, Walkner MM, Gupta RS. Quality of life among food allergic patients and their caregivers. Curr Allergy Asthma Rep 2016;16:38CrossRefGoogle Scholar
  3. 3.
    Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics 2011;128:e9–e17CrossRefGoogle Scholar
  4. 4.
    Peters RL, Koplin JJ, Gurrin LC, Dharmage SC, Wake M, Ponsonby AL, et al. The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4 year follow-up. J Allergy Clin Immunol 2017;140:145–153e8CrossRefGoogle Scholar
  5. 5.
    Savage JH, Matsui EC, Skripak JM, Wood RA. The natural history of egg allergy. J Allergy Clin Immunol 2007;120:1413–7CrossRefGoogle Scholar
  6. 6.
    Skripak JM, Matsui EC, Mudd K, Wood RA. The natural history of IgE-mediated cow's milk allergy. J Allergy Clin Immunol 2007;120:1172–7CrossRefGoogle Scholar
  7. 7.
    Begin P, Paradis L, Paradis J, Picard M, Des Roches A. Natural resolution of peanut allergy: a 12-year longitudinal follow-up study. J Allergy Clin Immunol Pract 2013;1:528–530e1–4CrossRefGoogle Scholar
  8. 8.
    Vander Leek TK, Liu AH, Stefanski K, Blacker B, Bock SA. The natural history of peanut allergy in young children and its association with serum peanut-specific IgE. J Pediatr 2000;137:749–55CrossRefGoogle Scholar
  9. 9.
    Kostadinova AI, Willemsen LE, Knippels LM, Garssen J. Immunotherapy—risk/benefit in food allergy. Pediatr Allergy Immunol. 2013;24:633–44CrossRefGoogle Scholar
  10. 10.
    Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997;99:744–51CrossRefGoogle Scholar
  11. 11.
    Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA 2017;318:1798–809CrossRefGoogle Scholar
  12. 12.
    Nowak-Wegrzyn A, Fiocchi A. Is oral immunotherapy the cure for food allergies? Curr Opin Allergy Clin Immunol 2010;10:214–9CrossRefGoogle Scholar
  13. 13.
    Rolinck-Werninghaus C, Staden U, Mehl A, Hamelmann E, Beyer K, Niggemann B. Specific oral tolerance induction with food in children: transient or persistent effect on food allergy?. Allergy 2005;60:1320–2CrossRefGoogle Scholar
  14. 14.
    Hussey Freeland DM, Fan-Minogue H, Spergel JM, Chatila TA, Nadeau KC. Advances in food allergy oral immunotherapy: toward tolerance. Curr Opin Immunol 2016;42:119–23CrossRefGoogle Scholar
  15. 15.
    Rachid R, Umetsu DT. Immunological mechanisms for desensitization and tolerance in food allergy. Semin Immunopathol 2012;34:689–702CrossRefGoogle Scholar
  16. 16.
    Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J 2015;8:17CrossRefGoogle Scholar
  17. 17.
    Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014;133:621–31CrossRefGoogle Scholar
  18. 18.
    Vickery BP, Scurlock AM, Jones SM, Burks AW. Mechanisms of immune tolerance relevant to food allergy. J Allergy Clin Immunol 2011;127:576–84. quiz 85–6CrossRefGoogle Scholar
  19. 19.
    Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mechanisms, diagnosis and immunotherapy. Nat Rev Immunol 2016;16:751–65CrossRefGoogle Scholar
  20. 20.
    Jay DC, Nadeau KC. Immune mechanisms of sublingual immunotherapy. Curr Allergy Asthma Rep 2014;14:473CrossRefGoogle Scholar
  21. 21.
    Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009;124:292–300, e1–97CrossRefGoogle Scholar
  22. 22.
    Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 2009;124:286–91, 91 e1–6CrossRefGoogle Scholar
  23. 23.
    Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011;127:654–60CrossRefGoogle Scholar
  24. 24.
    Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014;383:1297–304CrossRefGoogle Scholar
  25. 25.
    Kukkonen AK, Uotila R, Malmberg LP, Pelkonen AS, Makela MJ. Double-blind placebo-controlled challenge showed that peanut oral immunotherapy was effective for severe allergy without negative effects on airway inflammation. Acta Paediatr 2017;106:274–81CrossRefGoogle Scholar
  26. 26.
    Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol 2014;133:468–75CrossRefGoogle Scholar
  27. 27.
    Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol 2017;139:173–181e8CrossRefGoogle Scholar
  28. 28.
    Nagakura KI, Sato S, Yanagida N, Nishino M, Asaumi T, Ogura K, et al. Oral immunotherapy in Japanese children with anaphylactic peanut allergy. Int Arch Allergy Immunol. 2018;175:181–8CrossRefGoogle Scholar
  29. 29.
    Bird JA, Spergel JM, Jones SM, Rachid R, Assa'ad AH, Wang J, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract 2018;6:476–485.e3CrossRefGoogle Scholar
  30. 30.
    Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. J Allergy Clin Immunol 2015;135:737–744e8CrossRefGoogle Scholar
  31. 31.
    Hsiao KC, Ponsonby AL, Axelrad C, Pitkin S, Tang MLK, Burks W, et al. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4 year follow-up of a randomised, double-blind, placebo-controlled trial. Lancet Child Adolesc Health 2017;1:97–105CrossRefGoogle Scholar
  32. 32.
    Dantzer JA, Wood RA. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy. 2018;48:232–40CrossRefGoogle Scholar
  33. 33.
    Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 2013;132:1368–74CrossRefGoogle Scholar
  34. 34.
    MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol 2017;139:873–881e8CrossRefGoogle Scholar
  35. 35.
    Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol 2012;129:448–455, 55 e1–5CrossRefGoogle Scholar
  36. 36.
    Mempel M, Rakoski J, Ring J, Ollert M. Severe anaphylaxis to kiwi fruit: Immunologic changes related to successful sublingual allergen immunotherapy. J Allergy Clin Immunol 2003;111:1406–9CrossRefGoogle Scholar
  37. 37.
    Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011;127:640–646e1CrossRefGoogle Scholar
  38. 38.
    Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 2013;131:119–127 e1–7CrossRefGoogle Scholar
  39. 39.
    Burks AW, Wood RA, Jones SM, Sicherer SH, Fleischer DM, Scurlock AM, et al. Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol 2015;135:1240–1248. e1CrossRefGoogle Scholar
  40. 40.
    Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol 2015;135:1275–1282 e6CrossRefGoogle Scholar
  41. 41.
    Andorf S, Purington N, Block WM, Long AJ, Tupa D, Brittain E, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol 2018;3:85–94CrossRefGoogle Scholar
  42. 42.
    Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, de Oliveira LC, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 2010;126:83–91 e1CrossRefGoogle Scholar
  43. 43.
    Anagnostou K, Clark A, King Y, Islam S, Deighton J, Ewan P. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy 2011;41:1273–81CrossRefGoogle Scholar
  44. 44.
    Chin SJ, Vickery BP, Kulis MD, Kim EH, Varshney P, Steele P, et al. Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. J Allergy Clin Immunol 2013;132:476–478 e2CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Wenming Zhang
    • 1
    • 2
  • Sayantani B. Sindher
    • 1
    • 2
  • Vanitha Sampath
    • 1
    • 2
  • Kari Nadeau
    • 1
    • 2
    • 3
    Email author
  1. 1.Sean N. Parker Center for Allergy and Asthma ResearchStanford UniversityStanfordUSA
  2. 2.Division of Pulmonary and Critical Care MedicineStanford UniversityStanfordUSA
  3. 3.Division of Allergy, Immunology and Rheumatology, Department of MedicineStanford UniversityStanfordUSA

Personalised recommendations